Zacks Research Forecasts GSK’s FY2027 Earnings (NYSE:GSK)

GSK plc (NYSE:GSK) – Equities research analysts at Zacks Research upped their FY2027 earnings per share estimates for GSK in a report released on Tuesday, March 25th. Zacks Research analyst E. Bagri now anticipates that the pharmaceutical company will post earnings per share of $5.05 for the year, up from their prior estimate of $5.04. The consensus estimate for GSK’s current full-year earnings is $4.14 per share.

GSK has been the subject of several other research reports. Morgan Stanley initiated coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GSK presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Trading Up 0.6 %

Shares of GSK stock opened at $38.74 on Thursday. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a market capitalization of $80.19 billion, a P/E ratio of 24.37, a P/E/G ratio of 1.12 and a beta of 0.58. GSK has a twelve month low of $31.72 and a twelve month high of $45.93. The stock’s fifty day simple moving average is $37.22 and its 200 day simple moving average is $36.79.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%.

Institutional Trading of GSK

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Dodge & Cox lifted its stake in GSK by 0.5% during the 4th quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company’s stock valued at $2,314,672,000 after acquiring an additional 353,749 shares in the last quarter. FMR LLC lifted its position in shares of GSK by 82.1% during the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company’s stock valued at $1,786,475,000 after purchasing an additional 23,814,104 shares in the last quarter. Primecap Management Co. CA boosted its holdings in GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock worth $854,349,000 after purchasing an additional 10,407,905 shares during the last quarter. Fisher Asset Management LLC grew its position in GSK by 1.4% in the 4th quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock worth $637,061,000 after purchasing an additional 259,867 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in GSK by 0.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company’s stock valued at $255,914,000 after buying an additional 35,134 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.06%. The ex-dividend date is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.